Therapy Areas: AIDS & HIV
Johnson & Johnson and global partners announce phase 2b Imbokodo HIV vaccine clinical trial results
1 September 2021 -

US-based healthcare company Johnson & Johnson (NYSE: JNJ), together with a consortium of global partners, announced on Tuesday results from the primary analysis of a Phase 2b HIV vaccine clinical trial known as the Imbokodo study (also known as HVTN 705/HPX2008).

Data showed the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. The investigational vaccine was found to have a favourable safety profile with no serious adverse events.

Based on these results, the Imbokodo study will not continue. Study participants will be notified of the results, unblinded and informed whether they were in the study group who received the vaccine or the group who received placebo. Further analysis of the Imbokodo study is ongoing, and the study has provided enough data to progress with key immunological correlates research.

Paul Stoffels, MD, vice chairman of the Executive Committee and chief scientific officer at Johnson & Johnson, was quoted as saying: "We are extremely grateful to the women who volunteered for the Imbokodo study, and to our partners, including the people on the frontlines, all of whom are contributing every day to this enduring quest to make HIV history.

"HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development because of its ability to attack, hijack and evade the human immune system. While we are disappointed that the vaccine candidate did not provide a sufficient level of protection against HIV infection in the Imbokodo trial, the study will give us important scientific findings in the ongoing pursuit for a vaccine to prevent HIV. We continue to stand in solidarity with people living with and vulnerable to HIV, and remain committed to furthering our research against this devastating virus."

Login
Username:

Password:


Related Headlines